Section 1: The Patent Cliff, Defined and Reframed What the Term Actually Means The phrase ‘patent cliff’ describes the sharp […]
Why Generic Drug Market Analysis Fails — and How to Fix It Most generic drug market analyses make the same
A deep-dive pillar for pharma IP teams, generic market strategists, portfolio managers, and institutional investors tracking ANDA timelines and biosimilar
REMS Weaponized: How Brand Pharma Turns Safety Programs Into $13.4B Competition Shields Read Post »
1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in
Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term
The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file
There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a
Top-Level Key Takeaways 1. What the Rule of Three Actually Is (and What It Isn’t) 1.1 The Economic Premise The
FDA’s Rule of Three: The Complete Playbook for How Generic Competition Kills Drug Prices Read Post »
1. Why the Generic Market Runs on Partnerships, Not Margins Generics and biosimilars filled 90% of all U.S. prescriptions dispensed
Sign in or create a free account to read this DrugPatentWatch article
